TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01858922
Drug: DECA
Normalized name: Decara
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine\*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide\*~\*Mix together in NS at an etoposide concentration of \</=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion.
Study: NCT01618513
Drug: Sandostatin® LAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections, dosage based on either GH or IGF-I levels.
Study: NCT03838133
Drug: TLC590
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients
Study: NCT03838133
Drug: Naropin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
Study: NCT03838133
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (0.9% sodium chloride, 10ml)
Study: NCT02715232
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
Study: NCT02715232
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
Study: NCT01139294
Drug: Hylenex
Normalized name: Hylenex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
Study: NCT02675374
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 minutes before CPB, patients will receive 2 ml of normal saline
Study: NCT03314363
Drug: NaCl predilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replace citrate predilution with NaCl
Study: NCT03314363
Drug: double ultrafiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
Study: NCT01431833
Drug: TR-701 FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dose 200 mg
Study: NCT01544517
Drug: Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
Study: NCT01558830
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
Study: NCT01669824
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
Study: NCT01082224
Drug: iodinated contrast dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodinated Radiocontrast dye for imaging enhancement
Study: NCT00096239
Drug: CP-547,632
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03769831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending dose oral adminstration
Study: NCT03017950
Drug: D086
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01362673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dose as matching placebo
Study: NCT01362673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral multiple doses as matching placebo for 12 days
Study: NCT01688882
Drug: QGE031
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
Study: NCT01034462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Study: NCT01688882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be used to control for normal variability in disease severity.
Study: NCT03011060
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
Study: NCT03255044
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin administered as well as standard heart failure therapy
Study: NCT00267358
Drug: RC-1291 HCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00267358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01334957
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
Study: NCT00873834
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized
Study: NCT00873834
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
Study: NCT01706263
Drug: MAXCLARITY II (2.5% BPO) Foam Cleanser
Normalized name: PERI-WASH II CLEANSER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available over the counter.
Study: NCT01706263
Drug: MAXCLARITY II (2.5% BPO) Foam Treatment
Normalized name: MaxClarity 2.5 % Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available over the counter.
Study: NCT02310763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02546024
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
Study: NCT00559364
Drug: Viokase® 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
Study: NCT00559364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
Study: NCT00559364
Drug: Proton pump inhibitor (PPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
Study: NCT04126343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding
Study: NCT01358084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
Study: NCT01004445
Drug: Amikacin (BAY41-6551)
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
Study: NCT01004445
Drug: Amikacin (BAY41-6551)
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
Study: NCT01004445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two aerosol treatments per day (one treatment every 12hr)
Study: NCT01118845
Drug: SyB L-0501
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation.
Study: NCT02615587
Drug: Standard of care in AF in Denmark
Approvals — FDA: no, EMA: no, PMDA: no
Description: As used in clinical practice, analysed as per drug class, not separate drugs.
Study: NCT04440280
Drug: N-acetyl cysteine (NAC) 10% solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.
Study: NCT04440280
Drug: N-acetyl cysteine (NAC) 20% solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.
Study: NCT01731886
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
Study: NCT02289690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to veliparib administered orally twice a day according to the dosing schedule.
Study: NCT03712124
Drug: CNSA-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNSA-001 Powder for Suspension
Study: NCT03712124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Suspension
Study: NCT04674709
Drug: Oleander 4X - single
Normalized name: NERIUM OLEANDER FLOWER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
Study: NCT04674709
Drug: Oleander 4X - double
Normalized name: NERIUM OLEANDER FLOWER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
Study: NCT04674709
Drug: Oleander 4X - quadruple
Normalized name: NERIUM OLEANDER FLOWER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
Study: NCT04674709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
Study: NCT01310361
Drug: Intramuscular Benzathin Penicillin G
Normalized name: Penicillin G Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
Study: NCT01899326
Drug: Desipramine Hydrochloride
Normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03573817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo version of Revefenacin is administered via a nebulizer.
Study: NCT04273217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
Study: NCT01396421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily, for six weeks
Study: NCT03182751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Looks exactly like the study drug, but it contains no active ingredient
Study: NCT00957216
Drug: Placebo (sugar pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: 2 wafers 4 times a day
Study: NCT00503113
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg intravenous (iv) injection every 3 months
Study: NCT00503113
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg intravenous (iv) infusion every 3 months
Study: NCT04644627
Drug: Gentamicin Sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical gentamicin ointment on wounds once daily for 6 weeks
Study: NCT00820508
Drug: CHR-2845
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
Study: NCT00329160
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5-20 mg
Study: NCT00329160
Drug: HMG CoA inhibitor
Normalized name: HMG CoA reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hydroxy-3-methylglutaryl-coenzyme A
Study: NCT03135340
Drug: WALANT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
Study: NCT03135340
Drug: Regional Anesthetic Injection
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
Study: NCT04491916
Drug: irone sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
Study: NCT00401245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering placebo
Study: NCT01230645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
Study: NCT00230594
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
Study: NCT00891072
Drug: R-(-)-gossypol acetic acid
Normalized name: citronellol acetate, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT04920370
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuPH20 will be administered via SC route.
Study: NCT04920370
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via SC route.
Study: NCT04920370
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via IV route.
Study: NCT01247740
Drug: NuTRIflex Lipid peri
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: parenteral nutrition
Study: NCT01374620
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days
Study: NCT00664287
Drug: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
Study: NCT02333188
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02333188
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00623636
Drug: MAP0004
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
Study: NCT00623636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
Study: NCT03838341
Drug: Oral anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy discontinuation - according to the standard of care at the discretion of the Investigator.
Study: NCT02451306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See information in arm description.
Study: NCT01959490
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01959490
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04500132
Drug: Placebo EC-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo EC-18 QD
Study: NCT02842021
Drug: S2G6T-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day topical cream
Study: NCT01780480
Drug: Dynamic Chinese herbal granule formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
Study: NCT02842021
Drug: S2G6T-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day topical cream
Study: NCT02842021
Drug: S2G6T-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day topical cream
Study: NCT02842021
Drug: S2G6T-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day topical cream
Study: NCT00872157
Drug: BMTP-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
Study: NCT01780480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
Study: NCT02849236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL saline 0.9%
Study: NCT02246764
Drug: AR-13324 Ophthalmic Solution 0.02%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop once daily (QD), PM, OU
Study: NCT01170507
Drug: Placebo orally daily for 5 months
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02246764
Drug: AR-13324 Ophthalmic Solution 0.02% BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop BID, AM/PM, OU
Study: NCT02335294
Drug: TRV130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue: Ibuprofen, oxycodone
Study: NCT02335294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue: Ibuprofen, oxycodone
Study: NCT03657238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single S.C. dose of placebo for subjects in placebo group
Study: NCT02807441
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive different doses of aspirin perioperatively to assess bleeding association.
Study: NCT00894842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
Study: NCT02347319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
Study: NCT01115855
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
Study: NCT01115855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily or every once daily
Study: NCT02238132
Drug: ATROVENT® inhalets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02079675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
Study: NCT04429867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
Study: NCT00367016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given by subcutaneous injection.
Study: NCT02457611
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT01254461
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4x100 mg per oral, twice daily for 8 days
Study: NCT01254461
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg, once daily at Day 1, period A and Day 8, period B
Study: NCT03110380
Drug: DTG Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT03110380
Drug: F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT03110380
Drug: B/F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily